1 / 13

RAVs Frequencies in Boceprevir Combination Treatment

Explore resistance-associated amino acid variants (RAVs) detected during Boceprevir plus PEGINTRON therapy. The study analyzes baseline RAVs in patients achieving sustained virologic response (SVR), RAV decline after treatment lead-ins, and RAV frequencies at virologic failure. Results show varying RAV decline rates in different patients. This research provides valuable insights into RAV dynamics during combination therapy for Hepatitis C.

thiery
Télécharger la présentation

RAVs Frequencies in Boceprevir Combination Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Frequencies of Resistance-Associated Amino Acid Variants (RAVs) detected by 454-sequencing during Combination Treatment with Boceprevir Plus PEGINTRON (PegInterferon Alfa-2b)/Ribavirin

  2. Introduction

  3. Aim

  4. Methods

  5. RAVs Detected at Baseline

  6. 454-Sequence analysis of Baseline RAVs in Patients that Achieved SVR (SPRINT-1)

  7. Decline in RAV viral load after 4-week Lead-in (SPRINT-2, RESPOND-2)

  8. RAVs Detected at Baseline Decline Following PegIntron/RBV treatment;Interferon Responsive Patients (SPRINT-2)

  9. RAV Frequencies after 4-week P/R lead-in(SPRINT-2/RESPOND-2)

  10. RAVs At Virologic Failure

  11. T54S Variant Detected at Baseline; Interferon Responsive Patient (SPRINT-2)

  12. RAVs Selected at Virologic Failure Decline at Different Rates During Follow-up Period (SPRINT-1)

  13. Conclusions

More Related